Vijay Reddy

Responsible to lead and shape in building Global Market Access strategy focused for new launch Products & drive Value Based Contracting (VBC) to gain favorable market access for its oncology and diabetes products majorly in EU and US markets and Emerging Markets spanning across Eastern Europe, ASEAN region and few countries from Middle East. Also, lead launching of DTx for Diabetes as paired offering for Biocon in US market and actively negotiating with payers & securing reimbursement with largest payer

Conceptualizing evidence generation strategy and delivering outcomes aligned with the product value propositions for Critical Care Solutions portfolio.

Global (affordable) pricing and market access strategy for a Japanese mid sized company Develop product commercialization strategy for a rare disease product by evaluating commercial potential and payor’s impressions of the likelihood of reimbursing the product (US mid-sized pharma) Develop global therapy area strategy spanning across geographies, different therapeutic class and BU's with a potential revenue upside (approx ~$50MN)

Cross border consulting assignments for clients on Product Pricing, Market Entry, Positioning & Business Growth Strategy Project 1: Formulated 4x (US$100 mn) business growth strategy for a (US$25 mn) US based company Identified key products for augmenting positioning of the firm in the US market Formulated strategy for partner selection & key growth markets outside US Project 2: Formulated global market entry/launch strategy for a product belonging to therapeutic class with market potential of US$2.7 bn

Consulted EU & US Pharma / Biotech majors in the areas Product Strategy, Market Access, Product Life Cycle Management, Pricing & Reimbursement Strategy, Product Portfolio Diversification Strategy Worked on various projects/assignments for different clients from major global pharmaceutical companies in US and Top 5 EU.

Quality Metrics benchmarking and redesigned existing quality parameters w.r.t changing business requirements.